Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 14/20 | 0.50 |
| ▸ | GIPR | P48546 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.44 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651098 | 0.87 | KDM4E (0.46) | GCGRGIPRCYP1A2VIPR2ENPP2 | |
| SCHEMBL2652185 | 0.84 | GCGR (0.60) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2655339 | 0.83 | HDAC1 (0.46) | GCGRRIPK2ENPP2PPARGDRD2 | |
| SCHEMBL2651771 | 0.82 | GCGR (0.44) | GCGRGIPRRIPK2PPARGDRD2 | |
| SCHEMBL2652045 | 0.81 | ENPP2 (0.51) | CYP1A2CYP3A4CYP2C9CYP2B6ENPP2 | |
| SCHEMBL2650795 | 0.79 | PPARG (0.47) | GCGRGIPRPPARG | |
| SCHEMBL2651979 | 0.78 | MAPT (0.55) | GCGRPPARGDRD2TBXA2R | |
| SCHEMBL2651226 | 0.76 | THRB (0.54) | PPARGDRD2TBXA2R | |
| SCHEMBL9251467 | 0.76 | JAK2 (0.49) | GCGRPPARGDRD2TBXA2R | |
| SCHEMBL9256074 | 0.75 | ITGB3 (0.54) | PPARGDRD2TBXA2RPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885CYP1A2 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.